This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CAH Stock May Gain Following the Distribution Agreement With Telix
by Zacks Equity Research
Cardinal Health and Telix announce an agreement selecting the former as a commercial radiopharmaceutical distributor to supply finished unit doses of Telix's Zircaix.
5 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Stocks like CCS, POWL, SLVM, IAG and UHS are seeing price strength and have a high chance of carrying the momentum forward.
HCA Healthcare Stock Up 18.4% in 3 Months: Can You Afford to Miss Out?
by Zubia Masood
HCA benefits from expanding insurance coverage, rising demand and improving margins.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
NSPR Stock Declines Despite PMA Application Submission for CGuard
by Zacks Equity Research
InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.
Tactile Medical's Shares Rise After PDAC Approval for Nimbl
by Zacks Equity Research
TCMD's Nimbl pneumatic compression system gets CMS PDAC approval and is set to be launched in the United States soon, following FDA clearance for treating lymphedema.
Community Health's Arm Northwest Urgent Buys 10 Arizona Facilities
by Zacks Equity Research
CYH expects the acquisition from Carbon Health to be completed in the fourth quarter of 2024.
Pediatrix Medical Up 45.8% in 3 Months: Is it Too Late to Jump In?
by Zacks Equity Research
MD remains one of the best-positioned pediatric service providers with favorable valuation to achieve margin improvement.
U.S. Fed Rate Cuts! Global Week Ahead
by John Blank
The Federal Reserve should deliver its first interest rate cut in four years, Brazil could hike for the first time since 2022 and Japan will be mindful of volatile markets.
CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
by Zacks Equity Research
CVRx announces the publication of positive study data for its Barostim therapy.
Masimo Stock Likely to Rise With Qualcomm Wear OS Partnership
by Zacks Equity Research
MASI Collaborates with Qualcomm to develop a reference platform for Wear OS smartwatches, combining biosensing tech and Snapdragon chips to enhance performance and connectivity.
The Zacks Analyst Blog Ubiquiti, Spotify, DocuSign, Vertiv and Universal Health
by Zacks Equity Research
Ubiquiti, Spotify, DocuSign, Vertiv and Universal Health are included in this Analyst Blog.
Buy 5 Large-Cap Growth Stocks for September on Rate Cut Expectations
by Nalak Das
Investment in growth stocks should be fruitful on rate cut hope. Five growth stocks to be purchased for September are DOCU, SPOT, UI, UHS and VRT.
Merit Medical Gains 26.4% Year to Date: What's Driving the Stock?
by Zacks Equity Research
MMSI's shares gain on the back of strength in its Cardiovascular segment and a robust product portfolio.
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
by Zacks Equity Research
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.
iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls
by Zacks Equity Research
IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology.
Cigna's Health Benefits Unit Launches a New E-Treatment Option
by Zacks Equity Research
CI's new launch, a new E-Treatment option, is expected to improve patient satisfaction and operational efficiency.
Avanos Medical Stock May Gain From Brand Partnership With NFL
by Zacks Equity Research
AVNS' GAME READY announces a paid partnership with NFL defensive end and San Francisco 49ers star, Nick Bosa.
Why Brookdale May Not Be a Safe Bet Despite 34-Month Occupancy Growth
by Zacks Equity Research
Rising operating costs due to inflationary challenges in the senior living industry and higher estimated insurance expenses are likely to keep BKD's margins under pressure.
PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing
by Zacks Equity Research
PACB's HiFi sequencing powers the HiFi Consortium's global effort to enhance the diagnosis and treatment of subfertility and recurrent pregnancy loss.
Solventum Shares May Gain on the Launch of Its New V.A.C Therapy
by Zacks Equity Research
SOLV announces the launch of its V.A.C. Peel and Place Dressing for providing efficient and effective care in case of negative pressure wound therapy.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
PacBio's Stock Up on Munster Deal for Male Infertility Research
by Zacks Equity Research
PACB collaborates with the University Hospital of Munster, using Revio HiFi sequencing to advance research on male infertility and rare diseases in Germany and globally.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Find "Strong Buy" Stocks Trading at Highs
by Benjamin Rains
Exploring a screen that helps investors find stocks experiencing impressive upward earnings revisions activity, helping them earn Zacks Rank #1 (Strong Buys). The stocks we screen for are also momentum names trading near 52-week highs.